Cargando…
Real‐world clinical practice of pulmonary arterial hypertension in Japan: Insights from a large administrative database
Pulmonary arterial hypertension (PAH) is a fatal disease that often occurs at an early age. In recent years, aggressive treatment with multiple drugs from the early‐stage diagnosis is expected to improve the prognosis. Indeed, a high rate of initial combination therapy and excellent treatment outcom...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462924/ https://www.ncbi.nlm.nih.gov/pubmed/37649808 http://dx.doi.org/10.1002/pul2.12275 |
_version_ | 1785098141869015040 |
---|---|
author | Omura, Junichi Kitahara, Kazuki Takano, Masashi Idehara, Koki Kim, Seok‐Won |
author_facet | Omura, Junichi Kitahara, Kazuki Takano, Masashi Idehara, Koki Kim, Seok‐Won |
author_sort | Omura, Junichi |
collection | PubMed |
description | Pulmonary arterial hypertension (PAH) is a fatal disease that often occurs at an early age. In recent years, aggressive treatment with multiple drugs from the early‐stage diagnosis is expected to improve the prognosis. Indeed, a high rate of initial combination therapy and excellent treatment outcomes have been reported from specialized centers for PAH in Japan. However, information on PAH epidemiology, including non‐PAH specialized centers in Japan, is unclear. To address the above, we conducted a retrospective observational cohort study from April 2008 to September 2020 using real‐world evidence from a large‐scale administrative database (Medical Data Vision) to examine baseline characteristics, comorbidities, and treatment profiles of Japanese patients with PAH. Five hundred and eighteen patients with PAH (treatment‐naive PAH, age 67.2 ± 15.9) were identified through our comprehensive approach which combined PAH disease codes, medications, and diagnostic procedures. Moreover, we showed that a larger proportion of patients received monotherapy in their initial treatment (66%) compared to those receiving combination therapy (34%). During the 1‐year follow‐up after PAH diagnosis, 13% of patients increased their PAH medications while other patients either decreased their PAH medications (6%) or discontinued PAH treatment (27%). The 3‐ and 5‐year event‐free survival rates of all‐cause death were 72% and 64%, respectively. This is the first large‐scale administrative database study that provides insights into real‐world PAH management in Japan. This study highlighted a different PAH clinical landscape which included a larger portion of the elderly population, higher initial monotherapy treatment, and lower survival rates than previous studies. |
format | Online Article Text |
id | pubmed-10462924 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104629242023-08-30 Real‐world clinical practice of pulmonary arterial hypertension in Japan: Insights from a large administrative database Omura, Junichi Kitahara, Kazuki Takano, Masashi Idehara, Koki Kim, Seok‐Won Pulm Circ Research Articles Pulmonary arterial hypertension (PAH) is a fatal disease that often occurs at an early age. In recent years, aggressive treatment with multiple drugs from the early‐stage diagnosis is expected to improve the prognosis. Indeed, a high rate of initial combination therapy and excellent treatment outcomes have been reported from specialized centers for PAH in Japan. However, information on PAH epidemiology, including non‐PAH specialized centers in Japan, is unclear. To address the above, we conducted a retrospective observational cohort study from April 2008 to September 2020 using real‐world evidence from a large‐scale administrative database (Medical Data Vision) to examine baseline characteristics, comorbidities, and treatment profiles of Japanese patients with PAH. Five hundred and eighteen patients with PAH (treatment‐naive PAH, age 67.2 ± 15.9) were identified through our comprehensive approach which combined PAH disease codes, medications, and diagnostic procedures. Moreover, we showed that a larger proportion of patients received monotherapy in their initial treatment (66%) compared to those receiving combination therapy (34%). During the 1‐year follow‐up after PAH diagnosis, 13% of patients increased their PAH medications while other patients either decreased their PAH medications (6%) or discontinued PAH treatment (27%). The 3‐ and 5‐year event‐free survival rates of all‐cause death were 72% and 64%, respectively. This is the first large‐scale administrative database study that provides insights into real‐world PAH management in Japan. This study highlighted a different PAH clinical landscape which included a larger portion of the elderly population, higher initial monotherapy treatment, and lower survival rates than previous studies. John Wiley and Sons Inc. 2023-08-29 /pmc/articles/PMC10462924/ /pubmed/37649808 http://dx.doi.org/10.1002/pul2.12275 Text en © 2023 Janssen Pharmaceuticals, K.K. and The Authors. Pulmonary Circulation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research Articles Omura, Junichi Kitahara, Kazuki Takano, Masashi Idehara, Koki Kim, Seok‐Won Real‐world clinical practice of pulmonary arterial hypertension in Japan: Insights from a large administrative database |
title | Real‐world clinical practice of pulmonary arterial hypertension in Japan: Insights from a large administrative database |
title_full | Real‐world clinical practice of pulmonary arterial hypertension in Japan: Insights from a large administrative database |
title_fullStr | Real‐world clinical practice of pulmonary arterial hypertension in Japan: Insights from a large administrative database |
title_full_unstemmed | Real‐world clinical practice of pulmonary arterial hypertension in Japan: Insights from a large administrative database |
title_short | Real‐world clinical practice of pulmonary arterial hypertension in Japan: Insights from a large administrative database |
title_sort | real‐world clinical practice of pulmonary arterial hypertension in japan: insights from a large administrative database |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462924/ https://www.ncbi.nlm.nih.gov/pubmed/37649808 http://dx.doi.org/10.1002/pul2.12275 |
work_keys_str_mv | AT omurajunichi realworldclinicalpracticeofpulmonaryarterialhypertensioninjapaninsightsfromalargeadministrativedatabase AT kitaharakazuki realworldclinicalpracticeofpulmonaryarterialhypertensioninjapaninsightsfromalargeadministrativedatabase AT takanomasashi realworldclinicalpracticeofpulmonaryarterialhypertensioninjapaninsightsfromalargeadministrativedatabase AT ideharakoki realworldclinicalpracticeofpulmonaryarterialhypertensioninjapaninsightsfromalargeadministrativedatabase AT kimseokwon realworldclinicalpracticeofpulmonaryarterialhypertensioninjapaninsightsfromalargeadministrativedatabase |